Меню
Идёт набор NCT06154083

INtensity of OVarian Stimualtion and Euploid Embryos

Фаза IV С лечением Fertility

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Follitropin-delta (Rekovelle) 20 mcg/day from D1, Follitropin-delta (Rekovelle) 15 mcg/day from D1.
Кому может быть актуально
Состояния в реестре: Fertility. Базовые параметры: 38 лет — 42 лет · Женщины.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Испания
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

The Impact of Ovarian Stimulation Intensity on Embryo Euploidy in Advanced Age Women

Обзор

This randomized trial was designed as a no-inferiority trial aiming to evaluate if the intensity of stimulation (a milder vs a more intense approach) may have an impact on the number of euploid embryos and the morpho kinetic parameters in advanced age women undergoing PGT-A with a PPOS protocol.

Вмешательства

  • Препарат Follitropin-delta (Rekovelle) 20 mcg/day from D1
    On day 2 or 3 of the menstrual cycle, daily injections of 20 mcg of Rekovelle (Stimulation Day 1) will be administered. Scan controls blood exams are performed on stimulation days 6, 8, 10 and, according to clinical needs, until trigger day. The dose will be the same during the whole course of stimulation and no dose adjustments will be performed.
  • Препарат Follitropin-delta (Rekovelle) 15 mcg/day from D1
    On day 2 or 3 of the menstrual cycle, daily injections of 15 mcg of Rekovelle (Stimulation Day 1) will be administered. Scan controls and blood exams are performed on stimulation days 6, 8, 10 and, according to clinical needs, until trigger day. The dose will be the same during the whole course of stimulation and no dose adjustments will be performed.

Первичные конечные точки

  • Number of euploid embryos [Срок оценки: Trough study completion, an average of 20-30 days.]
Вторичные конечные точки (12)
  • Gonadotropin dose [Срок оценки: Up to oocyte pickup, an average of 10-20 days]
  • Length of stimulation [Срок оценки: Up to oocyte pickup, an average of 10-20 days]
  • Estradiol [Срок оценки: Up to oocyte pickup, an average of 10-20 days]
  • Progesterone [Срок оценки: Up to oocyte pickup, an average of 10-20 days]
  • LH [Срок оценки: Up to oocyte pickup, an average of 10-20 days]
  • Follicular Output RaTe (FORT) [Срок оценки: Day one of stimulation. 1 Day]
  • Cycle cancelation rate [Срок оценки: Up to oocyte pickup, an average of 10-20 days]
  • Fertilization rate [Срок оценки: Up to one day after oocyte pickup, an average of 10-20 days]
  • Time of appearance of the 2nd polar body (tPB2) [Срок оценки: Up to one day after oocyte pickup, an average of 10-20 days]
  • Time of pronuclei disappearance (tPNf) [Срок оценки: Up to one day after oocyte pickup, an average of 10-20 days]
  • Time of division from 2 to 8 cells [Срок оценки: Until 1, or 4 days after insemination]
  • Time of compactation (tSC) [Срок оценки: Until 3, or 4 days after insemination]

Критерии участия

Критерии включения

  • Infertile patients with indication for IVF
  • Undergoing preimplantation genetic screening cycles
  • AMH >= 1.5 ng/ml and < 3.5 ng/ml (AMH result of up to one year will be valid)
  • BMI 18.5 - 30 Kg/m2

Критерии исключения

  • Severe male factor requiring TESE (testicular sperm extraction)
  • AMH < 1.5 ng/ml or >= 3.5 ng/ml
  • Administration of any other drug potentially interfering with the treatment
  • Contraindication for hormonal treatment
  • Recent history of severe disease requiring regular treatment (clinically significant concurrent medical condition that could compromise subject safety or interfered with the trial assessment).
  • Monogenic disease to be detected with PGT-M

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Открытое
Основная цель
Лечение

Центры проведения

Испания · 1 центр
  • Hospital Universitario Quiron Dexeus — Barcelona

Публикации

  • Alper MM, Fauser BC. Ovarian stimulation protocols for IVF: is more better than less? Reprod Biomed Online. 2017 Apr;34(4):345-353. doi: 10.1016/j.rbmo.2017.01.010. Epub 2017 Jan 24. PMID 28169189
  • Arce JC, Larsson P, Garcia-Velasco JA. Establishing the follitropin delta dose that provides a comparable ovarian response to 150 IU/day follitropin alfa. Reprod Biomed Online. 2020 Oct;41(4):616-622. doi: 10.1016/j.rbmo.2020.07.006. Epub 2020 Jul 15. PMID 32819842
  • Baart EB, Martini E, Eijkemans MJ, Van Opstal D, Beckers NG, Verhoeff A, Macklon NS, Fauser BC. Milder ovarian stimulation for in-vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial. Hum Reprod. 2007 Apr;22(4):980-8. doi: 10.1093/humrep/del484. Epub 2007 Jan 4. PMID 17204525
  • Briggs R, Kovacs G, MacLachlan V, Motteram C, Baker HW. Can you ever collect too many oocytes? Hum Reprod. 2015 Jan;30(1):81-7. doi: 10.1093/humrep/deu272. Epub 2014 Oct 31. PMID 25362088
  • Devesa M, Tur R, Rodriguez I, Coroleu B, Martinez F, Polyzos NP. Cumulative live birth rates and number of oocytes retrieved in women of advanced age. A single centre analysis including 4500 women >/=38 years old. Hum Reprod. 2018 Nov 1;33(11):2010-2017. doi: 10.1093/humrep/dey295. PMID 30272168
  • Franasiak JM, Forman EJ, Hong KH, Werner MD, Upham KM, Treff NR, Scott RT Jr. The nature of aneuploidy with increasing age of the female partner: a review of 15,169 consecutive trophectoderm biopsies evaluated with comprehensive chromosomal screening. Fertil Steril. 2014 Mar;101(3):656-663.e1. doi: 10.1016/j.fertnstert.2013.11.004. Epub 2013 Dec 17. PMID 24355045
  • Irani M, Canon C, Robles A, Maddy B, Gunnala V, Qin X, Zhang C, Xu K, Rosenwaks Z. No effect of ovarian stimulation and oocyte yield on euploidy and live birth rates: an analysis of 12 298 trophectoderm biopsies. Hum Reprod. 2020 May 1;35(5):1082-1089. doi: 10.1093/humrep/deaa028. PMID 32348476
  • Kok JD, Looman CW, Weima SM, te Velde ER. A high number of oocytes obtained after ovarian hyperstimulation for in vitro fertilization or intracytoplasmic sperm injection is not associated with decreased pregnancy outcome. Fertil Steril. 2006 Apr;85(4):918-24. doi: 10.1016/j.fertnstert.2005.09.035. PMID 16580375

Идентификаторы

NCT: NCT06154083 · FSD-INO-2023-14 · 2023-507028-22

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗